Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Licensing 96

Licensing Licensing Branding Drugs 96

Pharmaceutical Technology

OCTOBER 21, 2022

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.

Development 278

Development Production Licensing Licensing 278

Bio Pharma Dive

JULY 12, 2022

Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment.

Drugs 277

Drugs Licensing Licensing Development 277

Camargo

AUGUST 5, 2020

Whether you plan to out-license or commercialize your product, getting the label right matters. The post Developing Drug Products with the Label’s Commercial Value in Mind appeared first on Camargo.

Production 217

Production Development Drugs Licensing 217

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

FEBRUARY 15, 2024

GSK has exercised its option for a licence for Elsie Biotechnologies’ discovery platform to detect and develop new oligonucleotides.

Licensing 240

Licensing Licensing Development 240

Pharmaceutical Technology

MARCH 23, 2023

The deal gives Biohaven global rights for the development of BHV-8000, excluding regions of China. We look forward to advancing BHV-8000 into clinical development and uncovering the potential of neuroimmunomodulation for severe neurological disorders in desperate need of novel treatment options.”

Licensing 263

Licensing Licensing Clinical Development Development 263

Bio Pharma Dive

JUNE 24, 2021

The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena.

Licensing 323

Licensing Licensing Drugs Development 323

Pharmaceutical Technology

JANUARY 10, 2025

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.

Licensing 147

Licensing Licensing Development 147

Bio Pharma Dive

OCTOBER 22, 2024

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for its clinical-stage treatment reni-cel.

Gene Editing 290

Gene Editing In-Vivo Licensing Licensing 290

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MARCH 28, 2023

On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both argenx and the venture of UCHealth and the University License Equity Holdings.

Licensing 130

Licensing Licensing Development Antibody 130

Bio Pharma Dive

APRIL 12, 2023

For an upfront payment of $75 million, Novo gets an exclusive license to use Aspect Biosystems’ “bioprinting” technology to develop as many as four treatments for the diseases.

Licensing 315

Licensing Licensing Development 315

Pharmaceutical Technology

OCTOBER 11, 2024

XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics development.

Licensing 130

Licensing Licensing Development 130

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. The post Capsida Biotherapeutics and Prevail to develop CNS gene therapies appeared first on Pharmaceutical Technology.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.

Development 241

Development RNA Gene Therapy Genetics 241

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 290

Gene Editing Insulin Gene Licensing 290

Pharmaceutical Technology

FEBRUARY 26, 2025

RedHill has signed an exclusive licensing agreement with Hyloris for the global development and commercialisation of RHB-102 (Bekinda).

Development 147

Development Licensing Licensing 147

Bio Pharma Dive

MARCH 3, 2025

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing 246

Licensing Licensing Antibody Development 246

Pharmaceutical Technology

JANUARY 15, 2025

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

Development 147

Development Antibody Licensing Licensing 147

Pharmaceutical Technology

NOVEMBER 5, 2024

Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.

Licensing 243

Licensing Licensing Development 243

Pharmaceutical Technology

FEBRUARY 21, 2024

Contract development and manufacturing organisation Genezen has announced plans to license CSL’s Cytegrity lentivirus production system.

Licensing 130

Licensing Licensing Production Manufacturing 130

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. for patients with NTRK fusion cancer across all solid tumors.

Development 242

Development Bioequivalency Generic Drugs Production 242

Pharmaceutical Technology

JANUARY 2, 2023

South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.

Licensing 130

Licensing Licensing Production Sales 130

Pharmaceutical Technology

MARCH 25, 2025

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the formers ESK-001.

Development 130

Development Licensing Licensing 130

Bio Pharma Dive

MARCH 25, 2025

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a).

Licensing 216

Licensing Licensing Genetics Medicine 216

Fierce Pharma

NOVEMBER 8, 2024

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.

Licensing 137

Licensing Licensing Antibody Drugs 137

pharmaphorum

JUNE 13, 2024

AbbVie agrees $1.7bn deal with China's FutureGen to license an anti-TL1A inflammatory bowel disease therapy still in preclinical development

Licensing 114

Licensing Licensing Drugs Development 114

Bio Pharma Dive

OCTOBER 27, 2020

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

Licensing 271

Licensing Licensing Drugs Branding 271

Bio Pharma Dive

JANUARY 19, 2023

Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology.

Gene Editing 260

Gene Editing Licensing Licensing Gene 260

Pharmaceutical Technology

OCTOBER 17, 2023

SpliceBio will license Spark Therapeutics’ propriety protein splicing platform to develop a gene therapy for renal disease.

Gene Therapy 246

Gene Therapy Gene Licensing Licensing 246

Pharmaceutical Technology

MAY 3, 2023

Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.

Licensing 130

Licensing Licensing Development Sales 130

Pharmaceutical Technology

SEPTEMBER 15, 2023

Cure Genetics has entered a partnership and licensing deal with Frametact to develop gene therapy for familial neurological ailments.

Genetics 246

Genetics Gene Gene Therapy Licensing 246

Pharmaceutical Technology

OCTOBER 12, 2023

Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Under the terms, Biogen will handle all the development and commercial activities of ATV: Aβ, along with the related expenses.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Bio Pharma Dive

OCTOBER 9, 2024

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.

Medicine 164

Medicine Licensing Licensing Development 164

Pharmaceutical Technology

JULY 28, 2022

Rezafungin is a new, once-weekly echinocandin antifungal being developed by Cidara to treat and prevent serious fungal infections such as candidemia and invasive candidiasis in adults. It is also being developed for invasive fungal infection prophylaxis in adults who undergo allogeneic blood and marrow transplantation. “We

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147